MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1

touchMDT for touchONCOLOGY

MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC

Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC).

The multidisciplinary team:

Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA

This touchPODCAST is for HCPs outside of the UK  only.

This activity is supported by an independent medical education funding request from AstraZeneca.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/